Short-Term Efficacy and Safety of Camrelizumab-Based Treatment for Refractory or Metastatic Oesophageal Squamous Cell Carcinoma
Objectives: To evaluate the shortterm efficacy and safety of camrelizumab in combination with apatinib for refractory or metastatic oesophageal squamous cell carcinoma.
Methods: We retrospectively reviewed the medical records of 30 patients with refractory or metastatic oesophageal squamous cell carcinoma treated with camrelizumab in combination with apatinib at a single institution. The shortterm efficacy was evaluated according to the RECIST. The safety was evaluated by the CTCAE.
Results: Among all 30 patients, the ORR and DCR were 27% (8/30) and 63% (19/30), respectively. CR was achieved in 0% (0/30) of patients, PR in 27% (8/30), SD in 36% (11/30), and 37% (11/30) experienced PD. The median PFS interval was 3.7 (95% CI: 2.48−3.88) months, and the median OS outcome was not reached.
Conclusion: Our study reveals that camrelizumab in combination with apatinib is a promising therapy for patients with refractory or metastatic ESCC. This combination has a high response rate and favourable clinical safety.
1. Zhang HZ, Jin GF, Shen HB. Epidemiologic differences in esophageal cancer between Asian and Western populations. Chin J Cancer. 2012;31:281-6.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
3. Zhang B, Wang X, Li Q, Mo H, Song Y, Xu J, et al. Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma. Chin J Cancer Res. 2019;31:910-17.
4. Zhang WC, Wang P, Pang, QS. Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review. Ann Transl Med. 2020;8:1193.
5. Hong Y, Ding ZY. PD-1 Inhibitors in the Advanced Esophageal Cancer. Front Pharmacol. 2019;10:1418.
6. Markham A, Keam SJ. Camrelizumab: First Global Approval. Drugs. 2019;79:1355-61.
7. Burkart C, Bokemeyer C, Klump B, Pereira P, Teichmann R, Hartmann JT. A phase II trial of weekly irinotecan in cisplatinrefractory esophageal cancer. Anticancer Res. 2007;27:2845-8.
8. Palucka AK, Coussens LM. The Basis of Oncoimmunology. Cell. 2016;164:1233-47.
9. Guo W, Wang P, Li N, Shao F, Zhang H, Yang Z, et al. Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. Oncotarget. 2018;9:13920-33.
10. Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202-06.
11. Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, et al.Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. 2017;18:631-39.
12. Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, et al. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. JAMA Oncol. 2019;5:546-50.
13. Song Y, Wu J, Chen X, Lin T, Cao J, Liu Y, et al. A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. Clin Cancer Res. 2019;25:7363-69.
14. Huang J, Xu B, Liu Y, Lu P, Ba Y, Wu L, et al. Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial. Cancer Commun (Lond). 2019;39:16.
15. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541-50.
16. Li W, Wei Z, Yang X, Huang G, Han X, Ni Y, et al. Salvage therapy of reactive capillary hemangiomas: Apatinib alleviates the unique adverse events induced by camrelizumab in nonsmall cell lung cancer. J Cancer Res Ther. 2019;15:1624-28.
17. Scott AJ, Messersmith WA, Jimeno A. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today (Barc). 2015;51:223-9.